Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Atezolizumab
Synonyms
Therapy Description

Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1, and in combination with carboplatin and etoposide for small cell lung cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Atezolizumab Tecentriq RG7446|MPDL3280A Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 68 Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy or progressed on platinum-based chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>=50% or IC>=10%) and without EGFR or ALK alterations, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound in advanced or metastatic triple-negative breast cancer expressing PD-L1, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, and in combination with cobimetinib and vemurafenib in BRAF V600-mutated melanoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer no benefit Atezolizumab Phase III Actionable In a Phase III trial (IMblaze370), Tecentriq (atezolizumab) treatment did not improve median overall survival (7.1 vs 8.5 months, HR=1.19) compared to Stivarga (regorafenib) in patients with chemotherapy-refractory metastatic colorectal cancer, 91.7% of whom were microsatellite stable or microsatellite instability-low (Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018; NCT02788279). detail...
Unknown unknown lung non-small cell carcinoma not applicable Atezolizumab Clinical Study - Meta-analysis Actionable In a meta-analysis, compared to Taxotere (docetaxel), treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival (HR=0.69, p<0.001) in non-small cell lung carcinoma patients (PMID: 29270615). 29270615
Unknown unknown lung non-small cell carcinoma not applicable Atezolizumab Phase II Actionable In a Phase II trial (POPLAR), treatment with Tecentriq (atezolizumab) resulted in an improved median overall survival of 12.6 months compared to 9.7 months with Taxotere (docetaxel) in patients with previously treated non-small cell lung cancer, and increased PD-L1 expression level was associated with improved survival benefit (PMID: 26970723; NCT01903993). 26970723
Unknown unknown lung non-small cell carcinoma not applicable Atezolizumab FDA approved Actionable In a Phase III trial (OAK) that supported FDA approval, treatment with Tecentriq (atezolizumab) resulted in an improved median overall survival compared to Taxotere (docetaxel) (13.8 vs 9.6 months, HR=0.73, p=0.0003) in patients with previously treated non-small cell lung cancer (PMID: 27979383; NCT02008227). detail... 27979383
ARID1A mutant bladder urothelial carcinoma predicted - sensitive Atezolizumab Clinical Study - Cohort Actionable In a retrospective analysis, metastatic urothelial carcinoma patients from the IMvigor210 trial harboring an ARID1A mutation (n=62) demonstrated a greater overall survival (15.4 mo vs 8.2 mo; P=0.03) compared to patients with wild-type ARID1A (n=213) when treated with Tecentriq (atezolizumab) (PMID: 32554706; NCT02108652). 32554706
ERBB2 act mut lung non-small cell carcinoma decreased response Atezolizumab Clinical Study - Cohort Actionable In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721). 31085721
Unknown unknown invasive bladder transitional cell carcinoma no benefit Atezolizumab Phase III Actionable In a Phase III trial (IMvigor010). adjuvant Tecentriq (atezolizumab) did not improve disease-free survival (HR=0.89, p=0.2446) or overall survival (HR=0.85, p=0.1951) compared to observation in patients with high-risk muscle-invasive urothelial carcinoma, and resulted in more treatment discontinuation due to adverse effects than previous studies (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 5000-5000; NCT02450331). detail...
FGFR3 mutant transitional cell carcinoma no benefit Atezolizumab Phase II Actionable In a Phase II trial (IMVigor 210, CheckMate 275), Tecentriq (atezolizumab) (n=119) treatment resulted in similar response rate (24% vs 21%, p=0.8) in patients with FGFR3 mutant or wild-type metastatic transitional cell carcinoma (PMID: 31272788). 31272788
ALK rearrange lung non-small cell carcinoma no benefit Atezolizumab Guideline Actionable Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). detail...
ALK rearrange lung non-small cell carcinoma no benefit Atezolizumab Clinical Study - Cohort Actionable In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). 27225694
Unknown unknown transitional cell carcinoma not applicable Atezolizumab FDA approved Actionable In a Phase II trial that supported FDA approval, treatment with Tecentriq (atezolizumab) in advanced urothelial carcinoma patients resulted in an objective response rate of 15% (45/310) in all patients, and 26% (26/100) in patients with immune cell PD-L1 expression greater than or equal to 5%, and resulted in an overall survival of 8.6 mo in patients receiving treatment post-progression compared to 1.2 mo in patients receiving no treatment post-progression (PMID: 26952546, PMID: 28950298; NCT02108652). 26952546 28950298 detail...
Unknown unknown urinary bladder cancer no benefit Atezolizumab Phase III Actionable In a Phase III trial, Tecentriq (atezolizumab) did not result in improved survival in patients with bladder cancer (PMID: 28559560). 28559560
BRAF V600E lung non-small cell carcinoma not predictive Atezolizumab Clinical Study - Cohort Actionable In a retrospective analysis, non-small cell lung cancer patients harboring BRAF V600E did not demonstrate a significantly different response to treatment with either Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab) compared to patients with BRAF non-V600E mutations, demonstrating an objective response rate of 25% (3/12) vs 33% (3/9) (p=1.0) and median progression-free survival of 3.7 months vs 4.1 months (p=0.37) (PMID: 29723688). 29723688

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03465891 Phase II Atezolizumab Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma Terminated USA 0
NCT03768063 FDA approved Atezolizumab A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) Recruiting USA | CAN 27
NCT02400814 Phase I Atezolizumab MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03708224 Phase II Atezolizumab + Emactuzumab Atezolizumab Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma Recruiting USA 0
NCT04267237 Phase II Atezolizumab + RO7198457 Atezolizumab A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer Withdrawn 0
NCT02108652 Phase II Atezolizumab A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Active, not recruiting USA | CAN 6
NCT03337698 Phase Ib/II Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + CPI-444 Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + RO6958688 A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) Recruiting USA 7
NCT03029832 Phase II Atezolizumab Atezolizumab + MOXR0916 A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy Terminated USA | CAN 3
NCT04543617 Phase III Atezolizumab Atezolizumab + MTIG7192A A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (SKYSCRAPER-07) Recruiting USA 27
NCT03120676 Phase II Atezolizumab Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma Terminated USA 0
NCT04477759 Phase I Atezolizumab Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer (DEHART) Not yet recruiting USA 0
NCT02091141 Phase II Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT02848651 Phase II Atezolizumab A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST] Completed USA 0
NCT04665843 Phase II Atezolizumab + MTIG7192A Atezolizumab A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09) Not yet recruiting USA 12
NCT02486718 Phase III Atezolizumab Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer Active, not recruiting USA | CAN 20
NCT03614949 Phase II Atezolizumab SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer Recruiting USA 0
NCT03281954 Phase III Atezolizumab Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo Recruiting USA | CAN 0
NCT02410512 Phase I MOXR0916 Atezolizumab A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | CAN 5
NCT02008227 Phase III Docetaxel Atezolizumab A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK Completed USA | CAN 29
NCT02708680 Phase Ib/II Atezolizumab Atezolizumab + Entinostat Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In Unknown status USA 1
NCT04458922 Phase II Atezolizumab Testing Atezolizumab in Patients >= 2 Years Old With Newly Diagnosed, Unresectable, or Metastatic Clear Cell Sarcoma or Chondrosarcoma Recruiting USA 0
NCT03148418 Phase II Atezolizumab A Study in Participants Previously Enrolled in a Genentech? and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study Recruiting USA | CAN 35
NCT02792192 Phase Ib/II Atezolizumab + BCG solution Atezolizumab Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants Completed USA 0
NCT04157985 Phase III Nivolumab Ipilimumab Pembrolizumab Atezolizumab Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04710498 Phase II Atezolizumab Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma Not yet recruiting USA 0
NCT02031458 Phase II Atezolizumab A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH Completed USA | CAN 17
NCT04610684 Phase II Atezolizumab Atezolizumab + Carboplatin + Etoposide Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases Recruiting USA 0
NCT04637594 Phase III Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Recruiting USA 0
NCT03483012 Phase II Atezolizumab Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis Active, not recruiting USA 0
NCT04751929 Phase II Abemaciclib + Atezolizumab Atezolizumab Abemaciclib Abemaciclib With or Without Atezolizumab for mCRPC Not yet recruiting USA 0
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA 3
NCT03201458 Phase II Atezolizumab Atezolizumab + Cobimetinib Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01984242 Phase II Atezolizumab Sunitinib Atezolizumab + Bevacizumab + Capecitabine A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma Completed USA 8
NCT03237780 Phase II Atezolizumab Atezolizumab + Eribulin Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Recruiting USA 0
NCT03014648 Phase II Atezolizumab Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT02784483 Phase I Atezolizumab Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma Terminated USA 0
NCT02450331 Phase III Atezolizumab A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010) Active, not recruiting USA | CAN 22
NCT04563338 Phase II Atezolizumab Atezolizumab + Bevacizumab Study of How Atezolizumab and Bevacizumab Affects the Tumors of Liver Cancer or Lung Cancer With Liver Metastases Not yet recruiting CAN 0
NCT04334941 Phase II Atezolizumab + Talazoparib Atezolizumab Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Recruiting USA 0
NCT04387084 Phase I Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy Not yet recruiting USA 0
NCT03473756 Phase Ib/II Atezolizumab Atezolizumab + Rogaratinib Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) Recruiting USA 7
NCT03178851 Phase I Atezolizumab Atezolizumab + Cobimetinib Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma Completed USA 8
NCT02304393 Phase I Selicrelumab Atezolizumab A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors Completed USA | CAN 4
NCT03206047 Phase Ib/II Atezolizumab + Guadecitabine Atezolizumab Atezolizumab + Guadecitabine + Rasdegafusp alfa Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT03555149 Phase Ib/II Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) Recruiting USA 6
NCT04310020 Phase II Atezolizumab Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients Recruiting USA 0
NCT02508870 Phase I Azacitidine Atezolizumab A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes Completed USA 0
NCT04402788 Phase II Atezolizumab Atezolizumab + Radiotherapy Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial Recruiting USA 0
NCT03197935 Phase III Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) Active, not recruiting USA | CAN 11
NCT02788279 Phase III Atezolizumab Atezolizumab + Cobimetinib Regorafenib A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma Completed USA | CAN 9
NCT03023423 Phase Ib/II Atezolizumab + Daratumumab Atezolizumab A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX) Completed USA 4
NCT02458638 Phase II Atezolizumab An Open Label Study of MPDL3280A in Advanced Solid Tumors Completed USA | CAN 16
NCT03452137 Phase III Atezolizumab A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting USA | CAN 21
NCT02463994 Phase I Atezolizumab A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC Completed USA 0
NCT03313804 Phase II Pembrolizumab Atezolizumab Nivolumab Priming Immunotherapy in Advanced Disease With Radiation Recruiting USA 0
NCT03869190 Phase Ib/II Atezolizumab + Tocilizumab Atezolizumab + Niraparib Atezolizumab + Hu5F9-G4 Atezolizumab + Enfortumab vedotin-ejfv Atezolizumab + Linagliptin Atezolizumab + Isatuximab Atezolizumab A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC) Recruiting USA 5
NCT02350673 Phase I Cergutuzumab amunaleukin Atezolizumab A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors Completed USA | CAN 4
NCT02302807 Phase III Paclitaxel Vinorelbine Atezolizumab Docetaxel A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed USA | CAN 27
NCT04272645 Phase II Abemaciclib + Atezolizumab Abemaciclib Atezolizumab Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer Withdrawn USA 0
NCT03178552 Phase II Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Atezolizumab + Cobimetinib + Vemurafenib Alectinib A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) Recruiting USA | CAN 26
NCT01903993 Phase II Atezolizumab A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - &quot;POPLAR&quot; Completed USA | CAN 11
NCT04214262 Phase III Atezolizumab Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Recruiting USA 0
NCT03620435 Phase II Atezolizumab Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer Unknown status CAN 0
NCT04300647 Phase II Atezolizumab Atezolizumab + MTIG7192A A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04) Recruiting USA | CAN 15
NCT02525757 Phase II Atezolizumab Carboplatin + Paclitaxel MPDL3280A With Chemoradiation for Lung Cancer Active, not recruiting USA 0
NCT02420821 Phase III Bevacizumab Sunitinib Atezolizumab A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma Active, not recruiting USA | CAN 19
NCT02609984 Phase II Atezolizumab G305 + ID-LV305 Trial of CMB305 and Atezolizumab in Patients With Sarcoma Terminated USA 0
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Recruiting USA 0
NCT02367794 Phase III Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA | CAN 24
NCT03115801 Phase II Atezolizumab Nivolumab A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers Active, not recruiting USA 0
NCT03024996 Phase III Atezolizumab A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) Active, not recruiting USA | CAN 26
NCT02997228 Phase III Atezolizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer Recruiting USA 0
NCT02927301 Phase II Atezolizumab A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT02409355 Phase III Carboplatin Cisplatin Gemcitabine Atezolizumab A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Terminated USA 13
NCT02367781 Phase III Atezolizumab Carboplatin + Nab-paclitaxel A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer Completed USA | CAN 6
NCT03424005 Phase Ib/II Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) Recruiting USA 7
NCT03191786 Phase III Atezolizumab Gemcitabine Vinorelbine A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naive Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) Active, not recruiting CAN 23
NCT02451423 Phase II Atezolizumab Study of MPDL3280A in Bladder Cancer Recruiting USA 0
NCT03141684 Phase II Atezolizumab Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery Recruiting USA 0
NCT03563716 Phase II Atezolizumab + MTIG7192A Atezolizumab A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Active, not recruiting USA 5
NCT03979066 Phase II Atezolizumab Atezolizumab + PEGPH20 Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC) Terminated USA 0
NCT02431208 Phase I Lenalidomide Atezolizumab A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM) Active, not recruiting USA 0
NCT02599454 Phase I Atezolizumab Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT01375842 Phase I Atezolizumab A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 3
NCT03056599 Phase I Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Recruiting USA 0
NCT02589717 FDA approved Atezolizumab An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy Approved for marketing USA 0
NCT02862275 Phase 0 Atezolizumab Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer Recruiting USA | CAN 0
NCT03102242 Phase II Atezolizumab Atezolizumab Immunotherapy in Patients With Advanced NSCLC Active, not recruiting USA 0
NCT03821246 Phase II Atezolizumab + Emactuzumab Atezolizumab Atezolizumab + Enzalutamide Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before Radical Prostatectomy Recruiting USA 0
NCT04660344 Phase III Atezolizumab A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011) Not yet recruiting USA | CAN 13
NCT03024437 Phase Ib/II Atezolizumab + Entinostat Atezolizumab + Bevacizumab + Entinostat Atezolizumab Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma Recruiting USA 0
NCT02409342 Phase III Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 18
NCT03513952 Phase II Atezolizumab + CYT107 Atezolizumab Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Recruiting USA 0
NCT02844816 Phase II Atezolizumab Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer Active, not recruiting USA | CAN 0
NCT04294810 Phase III Atezolizumab Atezolizumab + MTIG7192A A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01) Recruiting USA 25
NCT04322643 Phase II Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma Recruiting USA 0
NCT04273061 Phase II Atezolizumab Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) Recruiting CAN 0
NCT03340558 Phase II Atezolizumab Atezolizumab + Cobimetinib Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (ATELIER) Withdrawn USA 0
NCT02928406 Phase III Atezolizumab A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract Active, not recruiting CAN 31
NCT02541604 Phase I Atezolizumab A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors Terminated USA | CAN 9


Additional content available in CKB BOOST